



HEALTH

THIS PANDEMIC HAS GIVEN US ONE IMPORTANT LESSON.
WHEN WE **HEAL** OUR MIND, BODY, SPIRIT
AND ENVIRONMENT WE ARE IN THE
BEST OF **HEALTH**.

FINANCIAL SUMMARY

10 Years' Performance

₹ In lakhs

CAPITAL ACCOUNT

Particulars	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21
Share Capital	418	418	418	418	1,253	1,253	1,253	1,253	1,253	2,505
Reserves	6,503	7,145	8,171	9,672	10,958	12,802	13,709	15,207	14,968	16,559
Borrowings	702	52	-	-	211	-	244	439	4,456	1,360
Gross Block	1,936	2,294	2,387	2,295	3,361	3,364	2,640	6,036	9,510	9,737
Net Block	1,095	1,308	1,233	982	1,850	1,759	2,262	5,502	8,404	7,142

REVENUE ACCOUNT


Particulars	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21
Total Revenue	22,908	24,490	27,055	28,874	32,973	22,454	24,863	32,537	31,117	44,250
Earnings Before Interest, Tax, Depreciation and Amortization	1,987	1,939	2,733	3,518	4,024	2,713	2,529	3,423	2,698	5,512
Profit before Tax	1,805	1,768	2,548	3,186	3,794	2,759	2,342	3,240	1,916	3,855
Profit After Tax	1,285	1,253	1,759	2,199	2,580	2,005	1,651	2,337	1,431	2,844
Earnings Per Share (₹)	15.38	15.01	21.06	26.00	10.3	8.00	6.59	9.33	5.71	5.67
Dividend Per Share (₹)	5.50	6.00	7.75	7.00	2.50	2.50	2.75	2.75	2.75	1.50

Notes :

- 1) EPS & DPS reported w.e.f. FY 2015-16 is after giving effect to Bonus Issue of Shares in the ratio of 2:1 i.e. 2 Bonus Shares for each Equity Share held.
- 2) EPS & DPS reported w.e.f. FY 2020-21 is after giving effect to Bonus Issue of Shares in the ratio of 1:1 i.e. 1 Bonus Shares for each Equity Share held.
- 3) Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.
- 4) The Board of Directors of the Company has recommended a final dividend of ₹ 1.50/- per equity share of face value of ₹ 5/- each (30%), subject to shareholders' approval at the 61st Annual General Meeting after giving effect to Bonus Issue of Shares in the ratio of 1:1 i.e. 1 Bonus Share for each Equity Share held.


Total Revenue

₹ in Lakhs




EBITDA

₹ in Lakhs




Reserves

₹ in Lakhs



Outflow of Dividend

₹ in Lakhs



Note: * This includes Final Dividend of F.Y. 2018-19 of ₹ 831 lakhs and Interim Dividend of F.Y. 2019-20 of ₹ 831 lakhs.

The Board of Directors recommended a Final Dividend of ₹ 1.50/- per share i.e. 30% for the F.Y. 2020-21 subject to the approval of Shareholders.

CONTENTS

Particulars	Page Nos.
Vice Chairman's Message to the Shareholders	3
List of Board of Directors	4
List of Senior Management and Key Managerial Personnel	6
Corporate Information	7
Notice	8
Directors' Report	24
Management Discussion and Analysis	44
Corporate Governance Report	47
Certificate on Corporate Governance	63
Independent Auditor's Report	64
Balance Sheet as on March 31, 2021	72
Statement of Profit and Loss for the year ended on March 31, 2021	73
Cash Flow Statement	74
Notes to Financial Statements	77

Vice Chairman's Message to the Shareholders



Mr. Bipin N. Shah

Vice Chairman

Dear Shareholders,

Our Company has been bestowed with the responsibility of providing quality bulk drugs to formulation companies. We have a strong client base of 350 Indian/Multinational companies. During the financial year 2020-2021, the main challenge was to run the Company, despite several factors related to the pandemic lockdowns. These include:

- i) Picking and dropping employees
- ii) Social distancing
- iii) Sanitization
- iv) Ensuring pandemic related safety measures like wearing masks etc.

We have successfully performed throughout the year and provided timely service to all our esteemed clients.

As we reel under the effects of the second wave, we still continue to face similar challenges. With tremendous support

from staff and workers, we are confident that we will keep the wheels of production rolling.

It is my great pleasure to present to you our Company's 61st Annual Report in a nutshell.

Our operational revenue for the financial year 2020-2021 amounted to ₹ 43,196 lakhs as against ₹ 30,696 lakhs for the previous year, an increase of 40.70%

Our profit before tax as compared to last year has increased by 101.25% from ₹ 1,916 lakhs to ₹ 3,855 lakhs and profit after tax has increased by 99% from ₹ 1,431 lakhs to ₹ 2,844 lakhs.

We could achieve above good results in spite of huge depreciation of ₹ 1,508 lakhs for the financial year 2020-2021.

EXPANSION PROJECT:

Our "New Expansion project" is fully operational and due to this increased capacity, we hope to continuously achieve higher topline and bottom-line.

We continue to allocate total resources towards building the API and Bulk Drugs segment. Our R&D facility at Navi Mumbai works relentlessly on the development of newer and better pharmaceutical raw materials.

TRANSFORMATION:

In order to generate long term sustainable value for shareholders, businesses need to continuously involve and transform themselves to build a strong foundation for future growth.

At Anuh Pharma, we have decided on a transformational journey to ensure that the Company is aligned in tune with the times.

With warm regards,

Mr. Bipin N. Shah

Vice Chairman

Anuh Pharma Ltd.

Board of Directors



Mr. Jasvantlal G. Shah
Chairman



Mr. Bipin N. Shah
Vice Chairman



Mr. Lalitkumar P. Shah
Director



Mr. Bharat N. Shah
Director



Mr. Arun L. Todarwal
Director



Dr. (Ms.) Mita C. Dixit
Director

Board of Directors



Mr. Harmanbhai T. Patel
Director



Mr. Sandeep M. Joshi
Director



Mr. Samir J. Shah
Director



Mr. Ketan L. Shah
Director



Mr. Ritesh B. Shah
Joint Managing Director



Mr. Vivek B. Shah
Joint Managing Director


Senior Management & Key Managerial Personnel



Mr. Rajendrakumar C. Kotadia
Vice President - Marketing



Dr. Rajiv P. Sutar
Vice President - Technical



Mr. Darshan D. Rampariya
Chief Financial Officer



Mr. Sanjay V. Barhate
Vice President - Quality



Dr. Sushil J. Dheer
General Manager - R & D



Mr. Tejas S. Patel
General Manager - QA



Mr. Surendra U. Rai
Assistant General Manager - QC



Mr. Ketan N. Shah
Senior Marketing Executive



Mr. Gaurav S. Shah
Head Anti Malarials



Mr. Kaushal H. Shroff
Senior Marketing Executive



Mr. Nilesh S. Mohare
Assistant General Manager - QA



Ms. Ashwini S. Ambrale
Company Secretary &
Compliance Officer



Mr. Bhavesh S. Mudaliar
Assistant General Manager
- Production



Mr. Babu K. Moghaveera
Assistant General Manager
- Technical



Mr. Monil R. Shah
Marketing & Business
Development Executive

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

**Sixty-First Annual Report of the Board of Directors
with the Audited Statement of Accounts for the year ended March 31, 2021**

Board of Directors	<p>: Mr. Jasvantlal Shah Mr. Bipin Shah (Appointed w.e.f. 08/01/2021) Mr. Ritesh Shah (Re-designated w.e.f. 08/01/2021) Mr. Vivek Shah (Re-designated w.e.f. 08/01/2021) Mr. Lalitkumar Shah Mr. Bharat Shah Mr. Arun Todarwal Mr. Sandeep Joshi Mr. Harmanbhai Patel Dr. (Ms.) Mita Dixit Mr. Samir Shah Mr. Ketan Shah</p>	<p>Chairman - Independent Director Vice Chairman Joint Managing Director Joint Managing Director Director Director Independent Director Independent Director Independent Director Independent Director Director Director</p>	<p>(DIN: 00372600) (DIN: 00083244) (DIN: 02496729) (DIN: 02878724) (DIN: 00396345) (DIN: 00083354) (DIN: 00020916) (DIN: 00516409) (DIN: 07342390) (DIN: 08198165) (DIN: 00157396) (DIN: 00083326)</p>
Chief Financial Officer	: Mr. Darshan Rampariya		
Company Secretary & Compliance Officer	: Ms. Ashwini Ambrale		
Auditors	: M/s. Jayantilal Thakkar & Co. Chartered Accountants, (Firm Registration No. 104133W)		
Bankers	: HDFC Bank Ltd.		
Registrars and Transfer Agents	: Bigshare Services Private Limited 1 st Floor, Bharat Tin Works Building, Opp. Vasant Oasis Makwana Road, Marol, Andheri East, Mumbai 400059 Tel: +91-22-6263 8200 Fax: +91-22-6263 8299 Email: investor@bigshareonline.com Web: www.bigshareonline.com		
Registered Office	: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel : +91-22-6622 7575 Fax: +91-22-6622 7600 Email: anuh@sk1932.com Web: www.anuhpharma.com		
Factory	: E-17/3, 17/4 & E-18 MIDC, Tarapur, Boisar, Dist. Palghar - 401506 Tel : +91-7410055574/75		
R & D Division	: A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701 Tel : +91-22-4119 3333 Fax: +91-22-4119 3300 Email: research@anuhpharma.com Web: www.aplrnd.com		

NOTICE

SIXTY-FIRST ANNUAL GENERAL MEETING of the Members of ANUH PHARMA LIMITED will be held on Thursday, 19th August, 2021 at 11.00 AM through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2021, including Audited Balance Sheet as at March 31, 2021 and the Statement of Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon for the said year.
2. To declare a Final Dividend of ₹ 1.50/- per Equity Share of the Company for the financial year 2020-21.
3. To appoint a Director in place of Mr. Lalitkumar P. Shah (DIN: 00396345) who retires by rotation and, being eligible offers himself for re-appointment.
4. To appoint a Director in place of Mr. Ketan L. Shah (DIN: 00083326) who retires by rotation and, being eligible offers himself for re-appointment.

SPECIAL BUSINESS :

5. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹ 1,10,000/- plus applicable tax and reimbursement of the out of pocket expenses, if any, payable to Mr. Ankit Kishor Chande, Cost Accountant, (Certificate of Practice No. 34051) being a Cost Auditor, to conduct the audit of the Cost Accounting records related to Bulk Drugs of the Company for the financial year 2021-22, be and is hereby ratified.

RESOLVED FURTHER THAT Mr. Bipin Shah, Vice Chairman (DIN: 00083244), Mr. Ritesh Shah (DIN: 02496729), Mr. Vivek Shah (DIN: 02878724), Joint Managing Directors, Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Directors and the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution."

6. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modifications, amendments or re-enactments thereto for the time being in force) (hereinafter referred to as "the Act"), in pursuance of the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the provisions of the Articles of Association of the Company and subject to the approvals, consents, permissions and sanctions of appropriate and/or concerned authorities and subject to such other conditions and modifications, as may be prescribed, imposed or suggested by any of such appropriate and/or concerned authorities while granting such approvals, consents, permissions and sanctions and as agreed to by the Board of Directors of the Company, (hereinafter referred to as "the Board" which term shall deemed to include any Committee which the Board may have constituted or herein after constitute to exercise its powers including the powers conferred by this Resolution), the consent of the Members be and is hereby accorded to the appointment and re-designation of **Mr. Ritesh B. Shah (DIN: 02496729) & Mr. Vivek B. Shah (DIN: 02878724)** as Joint Managing Directors of the Company from the position of Whole Time Directors and Chief Executive Officers of the Company, for a period of 5 years with effect from 8th January, 2021 upto 7th January, 2026, whose period of office shall not be liable to retire by rotation, with the powers to the Board to alter, amend, vary and modify the terms and conditions of the said appointment.

RESOLVED FURTHER THAT Mr. Bipin Shah, Vice Chairman (DIN: 00083244) Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Directors and the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and